AllSci News
Tempest secures option on Senlang’s clinical-stage lentiviral in vivo CAR-T platform
California-based Tempest Therapeutics (Nasdaq: TPST) has secured an exclusive option to license China-based Hebei Senlang Biotechnology's CD7-targeted...
Japan approves Viatris’ Wakix for narcolepsy and OSAS-related daytime sleepiness
Japan's Ministry of Health, Labour and Welfare has approved Wakix (pitolisant) for two indications: excessive daytime sleepiness (EDS) associated with...
Elvinix picks up Zealand's GLP-1/gastrin portfolio for type 1 diabetes development
Delaware-based Elvinix Inc. has secured an exclusive worldwide license from Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) to develop and commercialize...
IASO Bio’s CD20-targeted in vivo CAR-T cleared for US study in B-NHL
China-based IASO Biotechnology received US FDA IND clearance for IASO208, an in vivo CD20-targeted CAR-T therapy for relapsed/refractory B-cell non-Hodgkin...
WHO review highlights SynAct’s resomelagon among six dengue drugs for further development
A World Health Organization review of the dengue therapeutic pipeline has identified resomelagon as one of six candidates with sufficient supporting...
ReEmerge exits stealth with USD 37m Series A to advance TBI brain stimulation study
Minnesota-based ReEmerge, Inc. has launched from stealth with an oversubscribed USD 37 million Series A financing to advance an implantable deep brain...
Novartis exercises option to acquire Sironax blood-brain barrier delivery platform for USD 125m
Novartis (NYSE: NVS) has exercised its exclusive option to acquire Sironax's proprietary Brain Delivery Module (BDM) platform, completing a transaction...
Sensorion targets US IPO with SEC filing as it pivots to GJB2 gene therapy
France-based hearing loss biotech Sensorion (Euronext: ALSEN) has confidentially submitted a draft registration statement on Form F-1 to the US Securities...
Sling starts Phase III trial of oral TED therapeutic linsitinib
Michigan-based Sling Therapeutics has dosed the first patients in the ORBIT pivotal trial, a global Phase III study of linsitinib in moderate to severe...
Twist joins Lilly's TuneLab as preferred antibody characterization data provider
South San Francisco-based Twist Bioscience Corporation (Nasdaq: TWST) has joined Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform, as...
Pfizer follows AstraZeneca in pulling EU bladder cancer filing after CHMP concerns
Pfizer's European marketing authorization application for Zumrad (sasanlimab), a subcutaneous anti-PD-1 monoclonal antibody intended for use with Bacillus...
China grants breakthrough status to CSPC’s EGFR ADC in AGA-negative NSCLC
CSPC Pharmaceutical Group Ltd (HKEX: 01093) announced that China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy...
Takeda secures FDA Priority Review for oral TYK2 inhibitor zasocitinib
The US FDA has accepted for Priority Review a New Drug Application (NDA) from Takeda (NYSE: TAK) for zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2)...
Shennon raises USD 12m to advance three preclinical T-cell engagers
San Francisco-based Shennon Biotechnologies has raised USD 12 million in a new financing round and simultaneously disclosed three oncology programs built on...
Orvida secures Recordati-led financing for ontivatrep in rare genetic skin diseases
Israel-based Orvida Pharma Ltd, formerly Kamari Pharma, a clinical-stage biotechnology company developing treatments for rare and severe genetic skin...
The AllSci Brief
Free, systematic R&D and deal news. Daily.